Chapter/Section Purchase

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.2 Key Market Segments
1.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Segment by Type
1.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
2.1 Global Market Overview
2.1.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Landscape
3.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales by Manufacturers (2019-2024)
3.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Manufacturers (2019-2024)
3.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Sites, Area Served, Product Type
3.6 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Situation and Trends
3.6.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Chain Analysis
4.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Type (2019-2024)
6.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Type (2019-2024)
6.4 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Price by Type (2019-2024)
7 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Sales by Application (2019-2024)
7.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (M USD) by Application (2019-2024)
7.4 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Growth Rate by Application (2019-2024)
8 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmentation by Region
8.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales by Region
8.1.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales by Region
8.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Region
8.2 North America
8.2.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Teijin Pharma
9.1.1 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.1.2 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.1.4 Teijin Pharma Business Overview
9.1.5 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) SWOT Analysis
9.1.6 Teijin Pharma Recent Developments
9.2 Shire
9.2.1 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.2.2 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.2.4 Shire Business Overview
9.2.5 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) SWOT Analysis
9.2.6 Shire Recent Developments
9.3 Pfizer
9.3.1 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.3.2 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.3.4 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) SWOT Analysis
9.3.5 Pfizer Business Overview
9.3.6 Pfizer Recent Developments
9.4 Octapharma
9.4.1 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.4.2 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.4.4 Octapharma Business Overview
9.4.5 Octapharma Recent Developments
9.5 Momenta Pharmaceuticals
9.5.1 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.5.2 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.5.4 Momenta Pharmaceuticals Business Overview
9.5.5 Momenta Pharmaceuticals Recent Developments
9.6 Mitsubishi Tanabe Pharma Corporation
9.6.1 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.6.2 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.6.4 Mitsubishi Tanabe Pharma Corporation Business Overview
9.6.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
9.7 Kedrion
9.7.1 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.7.2 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.7.4 Kedrion Business Overview
9.7.5 Kedrion Recent Developments
9.8 Grifols
9.8.1 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.8.2 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.8.4 Grifols Business Overview
9.8.5 Grifols Recent Developments
9.9 CSL Behring (CSL Limited)
9.9.1 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.9.2 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.9.4 CSL Behring (CSL Limited) Business Overview
9.9.5 CSL Behring (CSL Limited) Recent Developments
9.10 Bio Products Laboratory
9.10.1 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.10.2 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.10.4 Bio Products Laboratory Business Overview
9.10.5 Bio Products Laboratory Recent Developments
9.11 Baxter
9.11.1 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.11.2 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.11.4 Baxter Business Overview
9.11.5 Baxter Recent Developments
9.12 MedDay Pharmaceuticals
9.12.1 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.12.2 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.12.4 MedDay Pharmaceuticals Business Overview
9.12.5 MedDay Pharmaceuticals Recent Developments
9.13 GeNeuro Pharmaceuticals
9.13.1 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Basic Information
9.13.2 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Overview
9.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Market Performance
9.13.4 GeNeuro Pharmaceuticals Business Overview
9.13.5 GeNeuro Pharmaceuticals Recent Developments
10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast by Region
10.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Forecast
10.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Forecast by Country
10.2.3 Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Forecast by Region
10.2.4 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Type (2025-2030)
11.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Type (2025-2030)
11.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast by Application (2025-2030)
11.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales (K Units) Forecast by Application
11.2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings